Abstract
Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent.
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / pathology
-
Female
-
Humans
-
Lymphoma, B-Cell / drug therapy*
-
Lymphoma, B-Cell / pathology
-
Rituximab
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Rituximab